Therapeutic vaccines for melanoma: Progress and problems
Therapeutic vaccines for melanoma: Progress and problems
复制标题
DOI：
10.1016/0167-7799(96)10045-7
复制
发表时间：
1996-09-01
影响因子：
17.3
通讯作者：
Mitchell, MS
中科院分区：
文献类型：
--
作者：
Jones, VE;Mitchell, MS
黑色素瘤疫苗已经开发多年，并根据实际测试中获得的知识不断完善。我们现在对他们的行动方式和尚待解决的问题有了更全面的了解。粗疫苗和纯疫苗都有值得推荐的地方——每种疫苗都有特定的优点，但都需要进一步开发。相关肽表位的分离、共刺激分子的添加、疫苗递送的新型载体和改进的疫苗佐剂的开发以及肿瘤诱导的免疫抑制问题是未来研究的课题。
Melanoma vaccines, which have been under development for many years, are being refined as a result of the knowledge gained from practical testing. We now have a more complete understanding of their mode of action and the problems that remain to be solved. There are points to recommend both crude and pure vaccines - each have specific advantages, but both require further development. Isolation of relevant peptide epitopes, addition of co-stimulatory molecules, the development of novel vehicles for vaccine delivery and improved vaccine adjuvants, and the problem of tumor-induced immunosuppression are among the issues for future study.